GlassScriptPhysician profile
Attefa Sultani
NPI 1740444975
$5,895.47
in general payments reported to CMS, 2019-2025
17 companies · $1,013 in 2025
The $1,013 reported for 2025 was more than what 91% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15.00 · 2021: $484 · 2022: $1,565 · 2023: $1,420 · 2024: $1,398 · 2025: $1,013.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,831.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,830.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $1,991.59 | 2021-2025 | Cequa |
| Coopervision INC. | $700.62 | 2022-2025 | Misight Contact Lens, Myday Contact Lens, Paragon Crt |
| Alcon Vision LLC | $610.68 | 2021-2025 | Precision7, Total30, Dailies Total1 |
| Bausch & Lomb Americas INC. | $596.99 | 2022-2025 | Xiidra, Miebo, Vyzulta |
| Biotissue Holdings INC. | $329.64 | 2022-2024 | |
| Tarsus Pharmaceuticals, INC. | $322.39 | 2024-2025 | Xdemvy |
| Abbvie INC. | $270.30 | 2023-2025 | Lumigan |
| Oyster Point Pharma, INC. | $237.48 | 2022-2024 | Tyrvaya |
| Glaukos Corporation | $216.12 | 2021-2024 | Idose |
| Eyevance Pharmaceuticals LLC | $199.17 | 2021-2022 | |
| Lumenis Be INC | $133.71 | 2022 | |
| Allergan, INC. | $99.80 | 2022 | |
| Harrow Eye, LLC | $82.49 | 2024-2025 | Ilevro, Vevye |
| Dompe US, INC. | $32.98 | 2022-2024 | Oxervate |
| Johnson & Johnson Vision Care, INC. | $29.29 | 2025 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abb Con-Cise Optical Group LLC | $27.22 | 2023 | Contact Lens, Spectacle Lenses |
| Alimera Sciences, INC. | $15.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Attefa Sultani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.